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Background: Epitope-mapping of infectious agents is essential for pathogenesis studies. Since polyclonal antibodies
(PAbs) and monoclonal antibodies (MAbs) are always polyspecific and can react with multiple epitopes, it is important
to distinguish between specific and non-specific reactions. Relative antibody discriminating specificity (RADS) values,
obtained from their relative ELISA reactions with L-amino acid peptides prepared in the natural versus reverse
orientations (x-fold absorbance natural/absorbance reverse = RADS value) may be valuable for this purpose.
PAbs generated against the dengue type-2 virus (DENV-2) nonstructural-1 (NS1) glycoprotein candidate vaccine also
reacted with both DENV envelope (E) glycoproteins and blood-clotting proteins. New xKGSx/xSGKx amino acid motifs
were identified on DENV-2 glycoproteins, HIV-1 gp41 and factor IXa. Their potential roles in DENV and HIV-1
antibody-enhanced replication (AER) and auto-immunity were assessed.
In this study, a) RADS values were determined for MAbs and PAbs, generated in congeneic (H2: class II) mice against
DENV NS1 glycoprotein epitopes, to account for their cross-reaction patterns, and b) MAb 1G5.3 reactions with xKGSx/
xSGKx motifs present in the DENV-4 NS1, E and HIV-1 glycoproteins and factor IXa were assessed after the introduction
of amino acid substitutions, deletions, or intra-/inter-cysteine (C-C) bridges.
Results: MAbs 1H7.4, 5H4.3, 3D1.4 and 1G5.3 had high (4.23- to 16.83-fold) RADS values against single epitopes on the
DENV-2 NS1 glycoprotein, and MAb 3D1.4 defined the DENV complex-conserved LX1 epitope. In contrast, MAbs
1G5.4-A1-C3 and 1C6.3 had low (0.47- to 1.67-fold) RADS values against multiple epitopes. PAb DENV complex-reactions
occurred through moderately-high (2.77- and 3.11-fold) RADS values against the LX1 epitope. MAb 1G5.3 reacted with
xSGKx motifs present in DENV-4 NS1 and E glycoproteins, HIV-1 gp41 and factor IXa, while natural C-C bridge
formations or certain amino acid substitutions increased its binding activity.
Conclusions: These results: i) were readily obtained using a standard 96-well ELISA format, ii) showed the LX1 epitope
to be the immuno-dominant DENV complex determinant in the NS1 glycoprotein, iii) supported an antigenic
co-evolution of the DENV NS1 and E glycoproteins, and iv) identified methods that made it possible to determine the
role of anti-DENV PAb reactions in viral pathogenesis.
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Synthetic peptides, covalently attached to solid-phase
supports or displayed on phage particles so that each
amino acid side chain accessible to MAb or PAb binding
are powerful tools to precisely locate epitopes on a wide
range of viral proteins for studying pathogenicity, and
accessing potential vaccines and immunotherapies [1].
The rapid preparation of thousands of synthetic peptides,
covalently coupled by their carboxyl-termini, at uniform
concentrations (Chiron Mimetopes, UK) has greatly
facilitated such studies using the standard 96-well ELISA
format [2-4]. This method gave highly reproducible very
consistent results when numerous research groups
(n = 16) used it for B-cell epitope-mapping [5], and the
results obtained with duplicate peptides were very simi-
lar (Absorbance (Abs) ranges: 0.00 to 0.06) [6-8]. This
method avoided the problems encountered when short
peptides were adsorbed to solid-phase supports, and was
useful for studying the effects of inter- and intra-cysteine
bridge formation that occur in many B-cell epitopes.
When the three-dimensional structure of the antigen is
known, it is possible to select optimal peptide sequences
for testing the binding activity of MAbs and PAbs.
PAbs and MAbs, as well as T-cells, are able to react with
numerous epitopes that present little similarity in amino
acid sequence and which may also be present on auto-anti-
gens (host proteins) [9-14]. These ‘cross-reactions’ gave rise
to polyspecificity which has been described to epitope ‘de-
generacy’, ‘plasticity’ or to ‘molecular mimicry’ [15]. It has
been suggested that ‘poly-functional’ antibodies (i.e. those
able to bind to multiple epitopes) could be an advantage
for the host and account for promoting antibody matur-
ation [10], although such T-cell and B-cell reactions with
epitopes in host proteins could result in autoimmune dis-
ease. Despite considerable debate, there is no single
accepted theory to account for the acquired immune sys-
tem’s ability to avoid what was originally termed ‘Horror
Autotoxicosis’ [13,16-18]. A number of factors are believed
to contribute to antigenic ‘polyspecificity (cross-reactions)
such as hydropathic complementarity [19,20] and epitope
length, since long peptides which contained identical tri-
and tetra- amino acid sequences was sufficient to result in
cross-reactions [21]. It has been extremely difficult to de-
sign vaccine candidates by the reconstruction of native
structures of viral neutralization epitopes using synthetic
peptides [14,22]. Synthetic peptides have however been
very useful for identifying many epitopes that were com-
mon to the dengue virus (DENV) nonstructural-1 (NS1)
glycoproteins and proteins from human thrombocytes,
endothelial cells and blood-clotting factors [6,23]. Since the
DENV NS1 glycoprotein is a candidate vaccine, it is essen-
tial to fully evaluate the role of these PAb cross-reactions in
pathogenesis by performing these experiments in vivo
under normal physiological conditions [23,24].The dengue viruses (DENVs) are important pathogens of
humans and, since they exist as four discrete serotypes, they
may cause four sequential infections in many countries
where all four DENV serotypes co-circulate [25]. The
DENVs are immunologically interesting due to evidence of
strain variation in their pathogenic capacities, and because
PAbs generated against one DENV serotype are able to
increase the replication of heterologous DENV serotypes in
Fcγ receptor-bearing monocytes/macrophages using either
PAbs or MAbs in vitro or in vivo [26,27]. While this
phenomenon is generally termed ‘antibody-dependent
enhancement’ (ADE), an alternative term ‘antibody-
enhanced replication’ (AER) was introduced to prevent con-
fusion with antibody-enhanced disease (AED) that occurred
in the absence of ADE [7,24]. The most severe and life-
threatening DENV disease, dengue haemorrhagic fever and
dengue shock syndrome (DHF/DSS) usually results from
secondary DENV infections [26-28], particularly by
DENV-2 and DENV-4 [28]. These observations were sup-
ported by finding that the 131-HH versus the 131-RR gen-
etic polymorphism in the FcγRIIa, which significantly
increased the binding of immune complexes containing
the human IgG1, IgG2 or IgG3 subclasses [29], which gen-
erated increased DENV AER, and was therefore a signifi-
cant DHF/DSS risk factor [30,31].
The generation of DENV-2 AER in vitro resulted in the
down-regulation of type-I interferon and RIG-I/MDA5-
signalling pathways and pro-inflammatory genes, thereby
allowing increased DENV replication to occur in vitro
[27,32-34]. These innate immune system genes were also
down-regulated in the acute-phase blood samples from
DHF/DSS patients [27,35,36], which further indicated that
DENV AER plays a key role in DHF/DSS pathogenesis. Of
particular concern for DENV vaccine development is the
fact that sub-neutralizing concentrations of all PAbs gener-
ated against any DENV serotype may result in their AER
[26]. Any candidate DENV vaccine must therefore gener-
ate appropriate, and life-long sustainable, neutralizing PAb
titers against each DENV serotype [37,38].
As a potential way to generate protective PAbs against all
four DENV serotypes, without the risk of DENV AER, the
DENV nonstructural-1 (NS1) glycoprotein was proposed as
a suitable candidate subunit vaccine [39,40]. The DENV
NS1 glycoprotein is however released as a homo-hexameric
glycoprotein at high concentrations from DENV-infected
cells con-currently with DENV virions. IgG responses
against these glycoproteins are only observed during the
acute-phase of secondary DENV infections [41], when most
DHF/DSS cases occur [26,28], and common epitopes were
identified on the DENV-2 NS1 and E glycoproteins [7].
Despite possessing RNA genomes, phylogenetic analyses
of the DENV-2 strains using their E glycoprotein-encoding
genes, together with antigenic analysis of their NS1 glyco-
proteins using MAbs, suggested that the DENV-2 E and
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ther supported by phylogenetic analyses of the E and NS1
glycoprotein-encoding genes of all four DENV serotypes
[43]. It was therefore hypothesized that common epitopes
on the E and NS1 glycoproteins could influence DENV
AER by either NS1 glycoproteins acting as ‘immunological
decoys’, or by the cross-reactions of PAbs generated against
the DENV NS1 glycoproteins with their E glycoproteins
[7]. This theory was recently supported by the demonstra-
tion that undiluted PAbs, raised against the DENV-2 NS1
glycoprotein in normal out-bred mice, also reacted with
epitopes on the DENV-2 E glycoprotein, and generated a
dramatic AER of a wild-type DENV-2 strain which
resulted in lethal multi-organ disease syndrome (MODS),
similar to that reported in DHF/DSS patients [24].
In contrast to single epitopes which were defined by
some MAbs on the DENV-2 NS1 glycoprotein [44], PAbs
and some MAbs were also generated against defined short
3-4-mer basic (K, R or sometimes H)-and/-or acidic (E or
D)-hydrophobic (usually L, I, or V)-basic (K, R or some-
times H) amino acid motifs present in either the natural or
reverse orientations, collectively termed ELK/KLE-type
and KELK/KLEK-type motifs [6,23]. These ELK/KLE-type
motifs were i) immuno-dominant in all congeneic (class II)
mouse tested, as well as in humans [7], ii) more strongly
detected by PAbs from DSS than DF patients, iii) more
strongly detected throughout the protein by both PAbs
from DSS patients and high responding (H-2b and H2s)
mouse haplotypes, and by MAb 1G5.4-A1-C3 than by its
low affinity sister clone, 1G5.4-A1-H6 [6,23], and iv) also
more numerous and/or antigenic in surface-exposed
regions of the DENV E glycoproteins from virulent (DHF/
DSS-associated) DENV-2 and DENV-3 strains [7], strongly
suggesting that they may have generated the DENV-2
AER/AED observed using undiluted anti-DENV NS1
glycoprotein sera [24]. These results also agreed with the
findings that: i) all of these PAbs cross-reacted with critical
sites in human blood-clotting factors (e.g. fibrinogen and
factor VII), platelets and endothelial cells [6,23], ii) fibrino-
gen was the dominant auto-antigen identified in DSS
patients’ circulating immune complexes [45], iii) epitope
density (numbers of similar exposed determinants/protein)
played a key role in immunogenicity and antigenicity
[46-49] and iv) in multiple infectious diseases such immu-
nodominant repetitive determinants diverted the hosts’
immune responses [50-56]. It seems likely therefore that
repetitive motifs in DENV proteins such as the ELK/KLE-
type motifs, which were more numerous and/or antigenic
in the main envelope (E) glycoproteins of virulent (DHF/
DSS-associated) DENV strains [7], play an important role
in the pathogenesis of DHF/DSS through increased AER/
AED.
In addition, to the ELK/KLE-type and KELK/KLEK-
type motifs, other short (e.g. SGK/KGS-type) motifs werealso identified on the DENV NS1 glycoproteins. These
sites contained degenerate amino-acids in their flanking
xSGKx/xKGSx regions, whilst the core SGK sequence
was maintained. The xKGSx motif was identified in a
neutralizing epitope on the E glycoproteins of all DENV
serotypes [8], while xSGKx motifs were uniquely located
in exposed neutralizing regions of domain II and III of
the DENV-4 E glycoprotein. The xSGKx motif was also
identified within an immuno-dominant epitope (600-
GIWGCSGKLICTTA-612 on the glycoprotein-41 (gp41)
of HIV-1 [57,58]. Stronger reactions against this epitope
were observed using PAbs from HIV-1-infected AIDS
versus non-AIDS patients, and these PAbs generated
HIV-1 AER via complement receptors [59]. In one study,
however, a human MAb that defined this epitope also
generated HIV-1 AER via a complement-independent,
Fcγ receptor-mediated mechanism [60]. The xSGKx
motif was also identified in the critical phospho-lipid
cell-binding site (1-YNSGKLEEFV-10) in the conforma-
tionally-dependent ω-loop of the Gla domain on acti-
vated mammalian vitamin K-dependent blood-clotting
factor IX [61].
PAbs generated by congeneic (class II) mouse strains
against the DENV-2 NS1 glycoprotein showed different
(DENV-2 type, DENV-2/-4 sub-complex and DENV-1
to −4 complex) reaction patterns with the NS1 glyco-
proteins of each DENV serotype [6,23]. The relative abil-
ity of MAbs and these PAbs to react with all of the
known sequential epitopes on the DENV-2 NS1 glyco-
protein, when they were prepared in the natural and
reverse orientations (relative antibody discriminating
specificity (RADS) (absorbance natural/absorbance
reverse = x-fold) values), were hypothesized to discrim-
inate between specific and non-specific MAb and PAb
reactions. In this case, these RADS values may be very
useful for identifying MAb and PAb reactions with the
DENV E glycoproteins or host auto-antigens, which
could generate DENVAER and/or auto-immunity.
This is therefore the first study attempting to:
A) determine the RADS values of MAbs that defined
single or multiple epitopes on DENV NS1 glycopro-
teins, B) determine and compare the RADS values of
the PAbs generated against the DENV-2 NS1 glyco-
protein by different congeneic (H-2 class II) mouse strains
with MAb RADS values, to account for their reaction
(DENV-2-type, sub-complex or complex) profiles against
the NS1 glycoproteins of each DENV serotype, C) deter-
mine the RADS values of MAb 1G5.3 against its DENV-2
NS1 glycoprotein target 24C epitope, and the xKGSx motif
present in a neutralizing epitope on the E glycoproteins of
all four DENV serotypes, D) assess the ability of MAb
1G5.3 to react with the xSGKx motifs in: i) DENV-4 NS1
and E glycoproteins, ii) an immuno-dominant HIV-1 gp41
epitope, and iii) a critical platelet-binding sequence in the
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epitopes contained intra-/inter-cysteine-bridges, amino acid
deletions or substitutions and more closely mimicked their
native protein conformations. Where possible, these reac-
tions were shown to be compatible with the location of the
epitopes in the three-dimensional structure of the protein.
The present study aimed to establish the value of this
new methodology for measuring: a) epitope reactions
when better peptide mimics were designed and tested, b)
the capacities of PAbs to generate AER of DENVs of
each serotype or of other infectious agents (e.g. HIV-1),
and c) the capacities of PAbs to cross-react with host
proteins (auto-antigens), that may be implicated in DHF/
DSS pathogenesis (through vascular leakage and/or
haemorrhage), or in other infectious and non-infectious
diseases.
Methods
Antigen preparation and purification
The growth of dengue viruses in mammalian cells and
the preparation of virus-infected cell sodium dodecyl
sulphate (SDS) lysates for Western blotting assays were
as described [7,23,62]. Briefly, dengue viruses of each
serotype (DENV-1 (Nauru Island strain), DENV-2
(PR159 and TR1751 strains), DENV-3 (H87 strain) and
DENV-4 (H-241 strain) were used to infect 70% conflu-
ent Vero cell monolayers maintained in medium 199
with 4% (vol/vol) foetal calf serum and antibiotics. After
incubation at 37°C for 5 days, the supernatants were col-
lected, the cell monolayers washed with medium 199,
and the infected cells homogenized using 0.5% (wt/vol)
sodium dodecyl sulphate (SDS) in 330 mM phosphoric
acid and 0.71% (wt/vol) Trisma base (pH 6.8). Aliquots
were stored at −80°C.
The immuno-affinity purification of the native homo-
hexameric extracellular/secreted (e/s) form of the NS1
(e/sNS1) glycoprotein was as described [6,7,23]. Briefly,
Vero cell monolayers (10 × 225 cm2 flasks) were infected
with DENV-2 (PR 159 strain), the supernatants were har-
vested on days 5 and 8 after infection, and: i) clarified by
centrifugation, ii) sodium azide and a cocktail of protease
inhibitors were added, iii) they were slowly passed
through an immuno-affinity column containing 12 mg of
MAb 2A5.1 covalently coupled to Sepharose 4B, iv) the
column was washed with PBS containing protease inhibi-
tors, v) the bound DENV-2 e/sNS1 glycoprotein was
eluted in the native form using 20 mM diethylamine in
PBS containing protease inhibitors (pH 11.2), and
vi) 500 μl fractions were immediately neutralized with
100 μl of 1 M Tris/HCl pH 7.2. Protein concentrations
were determined using an ELISA plate-adapted
bichinchonic acid (BCA) protein determination assay
(Pierce, USA) using standard 10 to 1,000 μg/ml) bovine
serum albumin concentrations, and Western blottinganalyses of each protein-containing fraction were per-
formed using MAb 1A12.3 as described [7,23,62].
Preparation and purification of mouse monoclonal
antibodies (MAbs)
The preparation of 173 MAbs against the native homo-
hexameric e/sNS1 form of DENV-2 (PR159 strain), and
the further characterization of MAbs 1H7.4, 5H4.3,
3D1.4, 1G5.3, 1C6.3 and 1G5.4-A1-C3, were previously
described [6,7,23,62]. Each of these MAbs reacted with
the native hexameric e/sNS1 form of the protein in
ELISA, and both the dimeric and monomeric forms of
these proteins in Western blot assays. These MAbs were
purified by binding to protein G-Sepharose 4B fast flow
(P-3296: Sigma, USA) using 0.1 M Na2HPO4 containing
300 mM NaCl (pH 7.2), eluted using 0.1 M glycine/HCl
(pH 2.7), and 1 ml fractions were immediately neutra-
lized with 100 μl of 1.5 M Tris/HCl (pH 7.8). The MAb
concentrations in each fraction were then determined
using the BCA assay (see above).
Polyclonal antibody (PAb) production
All of the studies using mice were performed under a
personal and project animal (scientific procedures)
licences (PIL 70/6903) issued by the Home Office, UK.
The immunization of congeneic mice with the native
purified hexameric DENV-2 e/sNS1 glycoprotein was as
described [6,23]. Briefly, groups of three 3-week old mice
of the B10.S, B10.RIII, B10.G, B10.BR, B10.A, B10.D2N
and C57BL/BJ strains were immunized using the com-
bined intra-peritoneal/subcutaneous (i.p/s.c.) routes with
10 μg of the purified DENV-2 (TR1751 strain) e/sNS1
glycoprotein emulsified in Freund's complete adjuvant,
boosted with the same antigen dose contained in PBS
two weeks later. Blood from each animal was collected a
further two weeks later, and their separated sera stored
at −80°C. A group of the high-responding B10.S strain
mice were immunized with 10 μg doses of ovalbumin
(A-7641 Sigma, USA) as controls using the same
methodology.
Peptide synthesis
The preparation and use of synthetic peptides, covalently
attached to polypropylene ‘pins’, ‘gears’ and ‘arrowheads'
(Chiron Mimetopes, United Kingdom), has been described
[6-8,23,44,62]. Briefly, duplicate synthetic peptide sequences
of epitopes identified by MAbs 1H7.4, 5H4.3, 3D1.4, 1G5.3,
1C6.3 and 1G5.4-A1-C3 on the DENV-2 NS1 glycoprotein
were prepared using activated Fmoc-protected L-amino
acid esters (Novabiochem, United Kingdom) in both natural
and reverse (unnatural) orientations on ‘gears/arrowheads’.
The amino-terminus of each peptide was then acetylated
and the side-chain protective groups removed using a
91.3% (wt/vol) trifluoroacetic acid (TFA) mixture. Peptide
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deletions, substitutions and intra-/inter-cysteine (C) bridge
(C-C) formations to test the reactions of MAb 1G5.3. The
surface-exposed target sequences on the DENV-4 E glyco-
protein were identified and confirmed by comparisons with
the corresponding sequences in high-resolution x-ray crys-
tallographic determinations of the dimeric forms of the
DENV-2 and DENV-3 E glycoproteins (http://www.ncbi.
nlm.nih.gov [MMBD ID 23080 and 32273]) [63,64]. Exam-
ples for MAb reaction studies with epitopes on other
viruses or human proteins were chosen since; a) a full ana-
lysis of the optimal peptide length and need for the intra-
cysteine bridge in the immuno-dominant epitope on gp41
of HIV-1 had been performed [57,58], b) high resolution X-
ray crystallographic data had been determined for the 600-
IWGCSGKLICTTA-612 epitope on HIV-1 gp41 [MMDB
ID 73687] [65] and c) high-resolution x-ray crystallo-
graphic data were available for the mammalian-conserved,
and Ca2+-stabilised/activated, γ-carboxyglutamic acid- (γE)-
rich (Gla domain (ω-loop)) epitope on blood-clotting factor
IXa (1-YNSGKLγEγEFV-10), bound by either a MAb
10C12 (Fab fragment [MMDB ID 25991] [66] or the snake
(Trimeresurus flavoviridis) venom protein, (IX/X-bp)
[MMDB ID 23297 and 23298] [67]. This region was es-
sential for the binding of factor IXa to platelet phosphati-
dylserine-containing phospholipid membranes, which act
as a stage for its subsequent activation of blood-clotting
factor X, but which was inhibited by both MAb 10C12 and
IX/X-bp [61,66,67].
Intra-peptide cysteine (C-C) bridges were prepared
using Fmoc-C(Trt) (N.B. Trt group was removed during
TFA treatment) for both cysteine (C) residues in the
peptides, with subsequent oxidation in air-saturated dis-
tilled water adjusted to pH 8.0 with 0.01 M NH4OH for
8 hours. In contrast, inter-peptide cysteine (C-C) bridges
were prepared by using Fmoc-C(Trt) for one of the C
residues and Fmoc-C(S-Acm) for the second C residue.
The first inter-C-C bond was formed by air oxidation
(see above), while the second inter-C-C bond was
formed by incubation of the peptides in 2 μM I2 in 20%
(vol/vol) methanol for 1 hour.
The RLX1 peptide sequence (110-LRYSWKTWG-
KAKMLSTEL-127C) differed from the KLX1 peptide
described previously [6,23] by containing the potentially
more antigenic arginine (R) residue at position 111 (under-
lined). This sequence was present in the DENV-2 NS1 gly-
coproteins of the PR159 and TR1751 strains used to
prepare the MAbs and immunize the congeneic mouse
strains, respectively. This peptide was prepared on 100–
200 mesh Cys(TrT)-Wang resin using HBTU/activated
Fmoc-protected amino acids on a multiple peptide
synthesizer (Zinsser Analytic SMPS350: Zinsser, United
Kingdom), and cleaved with a 91.3% (wt/vol) trifluoroace-
tic acid mixture. After being repeatedly precipitated in colddiethyl ether, the peptide was dried under argon. The add-
itional Boc groups were removed from the tryptophan (W)
residues by incubation with 20% (vol/vol) glacial acetic
acid/H2O for four hours at 25°C. This mixture was then
made to 5% (vol/vol) acetonitrile, loaded onto a prepara-
tive C18 reversed-phase column (Vydac, USA) and sub-
jected to high performance liquid chromatography
(Beckman Gold, USA) using a 5–95% (vol/vol) acetonitrile
gradient containing 1% (wt/vol) TFA (pH 2.0), and the
main peak was collected and freeze-dried.
Immunoassays
The indirect ELISAs, using purified hexameric e/sNS1
glycoprotein and synthetic peptides, have been described
[6,7,23,24,44]. For these assays, 96-well ELISA plates
were loaded with the purified DENV-2 e/sNS1 glycopro-
tein or the RLX1 peptide at 10 μg/ml (50 μl/well) diluted
in carbonate/bicarbonate buffer (pH 9.8) overnight at
4°C. After washing with PBS containing 0.05% (vol/vol)
Tween20 (PBS/T), they were blocked using 1% (wt/vol)
gelatin/PBS for 2 hours at 25°C, and after washing with
PBS/T, duplicate serial 3-4-fold dilutions of purified
mouse MAbs or PAbs from 1/20 were prepared in PBS/
T containing 0.25% (wt/vol) gelatin (PBS/T/G) and
allowed to react 37°C for 60 minutes. After washing with
PBS/T, the bound mouse antibodies were detected by se-
quential steps involving peroxidase-labeled goat anti-
mouse IgG (H&L) (115-035-166: Jackson ImmunoRe-
search, USA) in PBS/T/G, washing with PBS/T, incuba-
tion with o-phenylene diamine (opd) in citrate/
phosphate buffer (pH 5.0) containing H2O2, and the ab-
sorbance values measured at 490 nm (MRX: Dynex,
USA). The results were expressed as the average recipro-
cal log10 50% end-point titres (1/log10t50). For the pep-
tide-coated ‘gears/arrowheads’, 175 μl volumes of PBS/G
were used for the blocking, and the purified MAbs or
pooled PAbs collected from each congeneic mouse strain
were reacted at 50 times their average 1/log10t50 ELISA
titres obtained against the purified hexameric DENV-2
e/sNS1 glycoprotein in 96-well ELISA plates (150 μl/
well). All of the other steps were also performed using
150 μl volumes and the average absorbance values were
determined at 490 nm. These peptide coated gears/
arrowheads were then recycled as described previously
[6,7,23].
Non-reduced immunoblotting (Western blotting) was
performed using the DENV-infected cell lysates or puri-
fied DENV-2 e/sNS1 glycoprotein as described previ-
ously [6,7,23,24]. Briefly, serial 8.0-0.5 μl sample
dilutions of each of these lysates, or 100 ng of the
DENV-2 e/sNS1 glycoprotein, were: i) made to 10 μl in
1x stacking buffer containing 0.5% (wt/vol) SDS,
ii) heated at 100°C for 3 minutes, iii) subjected to elec-
trophoresis (15–20 constant mA/gel) on a 7% (wt/vol)
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electro-blotted at 160 mA/gel (Sartoblot II, Sartorius,
UK) onto 0.2 μm pore-size nitrocellulose membranes,
and v) air-dried. These membranes were then blocked
with 3% (wt/vol) skimmed milk powder/PBS (PBS/T/M)
containing 0.02% (wt/vol) NaN3 overnight. The DENV-
complex- reactive MAb 1A12.3 (2.5 μg/ml) was then
reacted with these membranes for 2 hours at 25°C. After
washing with PBS/T (4 × 5 minutes), the bound MAbs
were detected using sequential steps of washing with
PBS/T, peroxidase-labelled goat anti-mouse IgG (H&L)
(see above), and 4-chloro-1-naphthol/3,3’diaminobenzi-
dine 4HCl substrate in PBS containing H2O2. The reac-
tion intensities of this MAb was then used to adjust the
concentrations of the NS1 glycoproteins in the infected-
cell lysates of each DENV serotype to gauge the immu-
noblot cross- reactive intensities of the other MAbs and
PAbs generated against these glycoproteins.
Results
MAb and PAb ELISA and immunoblot reactions against
DENV NS1 glycoproteins and the RLX1 peptide
MAbs 1H7.4 (DENV-2 type-reactive: LD2 epitope),
5H4.3 (DENV-2/-4 sub-complex-reactive: 24A epitope),
3D1.4 (DENV-1 to −4 complex-reactive: LX1 epitope-
specific) and 1G5.3 (DENV-2/-4 sub-complex-reactive:
24C epitope-specific), which defined single sequential
epitopes on the DENV-2 NS1 glycoprotein [6,7,44],
strongly reacted with DENV-2 NS1 glycoprotein in the
ELISA (Table 1). Only MAb 3D1.4 strongly reacted with
the RLX1 peptide sequence (110-LRYSWKTWG
KAKMLSTEL-127C), which contained the antigenically-
conserved DENV complex LX1 epitope (underlined). In
contrast, MAbs 1C6.3 and 1G5.4-A1-C3 defined multiple
KELK- (basic-acidic-hydrophobic-basic amino-acid) and
ELK- (acidic-hydrophobic-basic amino-acid) type motifs
on DENV NS1 glycoproteins that were naturally present
in either orientations (e.g. KELK/KLEK and ELK/KLE).
MAb 3D1.4 displayed similar reaction intensities
against the NS1 glycoprotein of each DENV serotype,
while MAb 1C6.3 displayed weaker reactions against the
DENV-2 and DENV-3 NS1 glycoproteins, and MAb
1G5.4-A1-C3 showed a DENV-2>DENV-4>DENV-1>
DENV-3 reaction profile in the immuno-blot assays.
Congeneic (H-2 class II: I-A ± I-E) mouse strains,
immunized with the native form of the DENV-2 NS1
glycoprotein, all generated moderate to high PAb titres
against this homologous glycoprotein in the ELISA. The
B10.A (I-Ak), B10.BR (I-Ak,I-Ek) and B10.RIII (I-Ar,I-Er)
mouse strains possessed relatively low-responding class
II haplotypes (average 1/log10t50 ELISA titers ≤ 3.8), while
C57BL (I-Ab) and B10.S (I-As) mice were identified as
possessing high-responding class II haplotypes (average
1/log10t50 ELISA titers≥ 4.5). Only the PAbs generatedby these high-responding (C57BL and B10.S) mouse
strains strongly reacted with the RLX1 peptide and the
NS1 glycoprotein of all four DENV serotypes. These two
high-responding mouse strains therefore, uniquely,
appeared to generate PAbs against the LX1 epitope. In
contrast, the control B10.S (H2 I-As) mouse PAbs gener-
ated against ovalbumin (OA) failed to react with either
the DENV NS1 glycoproteins or the RLX1 peptide.
MAb reactions against single-target epitopes prepared in
the natural and reverse orientations using L-amino acids
The four MAbs, which defined single sequential epitopes
on the DENV-2 NS1 glycoprotein, reacted strongly with
their single-target epitope sequences when they were
prepared in the natural (+) orientation (Figure 1). MAb
1H7.4, which defined epitope LD2 (25-VHTWTEQYK-
33), had a very high 16.83-fold relative antibody discrim-
inating specificity (RADS) value, obtained from the com-
parison of its absorbance (Abs) against the natural/
reverse orientated target peptide sequences (Abs natural
(+) 2.02/Abs reverse (−) 0.12 = 16.83-fold RADS value)
(Figure 1, Table 2, Table 3). High RADS values were also
obtained for the other three MAbs. MAb 3D1.4 had a
15.00-fold RADS value against epitope LX1, MAb 1G5.3
had 12.36-fold RADS value against epitope 24C, and
MAb 5H4.3 had a 4.23-fold RADS value against epitope
24A. These four MAbs therefore had moderately-high
abilities to discriminate between their natural and
reverse orientated synthetic peptide target sequences.
MAb reactions against multiple epitopes prepared in the
natural and reverse orientations using L-amino acids
In contrast to the other four MAbs (Figure 1), MAbs
1C6.3 and 1G5.4-A1-C3, which defined KELK/KLEK-
type and ELK/KLE-type motifs respectively, reacted with
the N-TERM, 24A, N’LX1, LX2/1, LX2/2 and LX2/3
peptide sequences in the DENV-2 NS1 glycoprotein
(Figure 2). Both of these MAbs also reacted with the
LD2 epitope, possibly through its 31-QYK-33 sequence,
but only weakly with the LX1 and 24C epitopes. MAb
1C6.3 reacted most strongly with the LX2/1 peptide se-
quence (Abs 1.33), while MAb 1G5.4-A1-C3 most
strongly reacted with the N’LX1 peptide sequence (Abs
1.18) (partially over-lapping the LX1 epitope), when they
were prepared in their natural orientation. In contrast to
the high (4.2-16.8-fold) RADS values obtained for MAb
1H7.4, 5H4.3, 3D1.4 and 1G5.3 against their single target
peptide sequences (Figure 1), MAbs 1C6.3 and 1G5.4-
A1-C3 reacted almost equally, and sometimes more
strongly, against multiple peptide sequences when they
were tested in the reverse orientation (Figure 2). The
highest RADS values for MAb 1C6.3 were obtained
against the LX2/3 peptide sequence (1.67-fold RADS
value) and for MAb 1G5.4-A1-C3 against the N’LX1











D1V D2V D3V D4V
MAb
1H7.4 LD2 6.0 <1.5 ++++
5H4.3 24A 5.2 <1.5 +++ ++
3D1.4 LX1 5.4 4.7 +++ +++ +++ +++
1G5.3 24C 5.7 <1.5 +++ + +++
1C6.3 (KELK/KLEK) 4.5 1.7 +++ ++ ++ +++
1G5.4-A1-C3 (ELK/KLE) 5.2 1.9 ++ ++++ + +++
PAb (Haplotype)
C57BL/BJ (I-Ab) Multiple 4.5 2.9 +++ +++ ++ +++
B10.S (I-As) Multiple 4.7 3.0 ++ +++ ++ +++
B10.RIII (I-Ar,I-Er) Multiple 3.8 2.2 + ++ + +
B10.BR (I-Ak,I-Ak) Multiple 3.7 2.0 ++ +
B10.G (I-Aq) Multiple 4.0 2.1 ++
B10.D2N (I-Ad,I-Ed) Multiple 4.0 2.1 + + +
B10.A (I-Ak) Multiple 3.5 1.7 +
B10.S (C) I-As) Multiple <1.0 <1.5
aMonoclonal antibodies (MAbs) or polyclonal antibodies (PAbs) generated against the native hexameric.
DENV-2 NS1 glycoprotein or control protein (ovalbumin) (B10.S (C)) in congeneic mouse strains with the H2 class II (I-E and/or I-A molecule) haplotypes shown in
brackets.
bEpitope name or reaction with multiple epitopes (PAbs), or MAbs which defined multiple ELK/KLE-type and KELK/KLEK-type motifs in multiple peptide sequences
from the DENV-2 NS1 glycoprotein.
cReciprocal log10 50% end-point ELISA titers against immuno-affinity purified native hexameric DENV-2 (D2V) s/eNS1 glycoprotein and the RLX1 synthetic peptide.
dImmunoblot colour reaction intensity gauged on an arbitrary scale from negative (blank) to ++++ against the non-reduced NS1 glycoproteins of DENV-1 (D1V) to
DENV-4 (D4V).
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http://www.biomedcentral.com/1756-0500/5/208peptide sequence (1.26-fold RADS value) (Figure 2,
Table 2, Table 3). They had lower RADS values against
the 24A epitope and N’LX1 peptide sequence, and
reacted more strongly with the reverse-orientated 24AFigure 1 MAb reactions against single-target DENV-2 NS1 glycoprote
orientations. aMonoclonal antibody (MAb) name. bEpitope name on the D
or reverse (−) orientations. dAmino acid sequence position and single letter
against each duplicate peptide when the MAbs were diluted at 50 times th
DENV-2 e/sNS1 glycoprotein (standard deviation range, 0.00 (low values) toepitope sequence, thereby giving very low 0.47-fold
(MAb 1C6.3) and 0.62-fold (MAb 1G5.4-A1-C3) RADS
values against it. These two MAbs therefore showed low
abilities to discriminate between these natural andin peptide sequences prepared in natural and reverse
ENV-2 NS1 glycoprotein. cEpitope sequence prepared in the natural (+)
amino acid peptide sequence. eAverage ELISA absorbance (490 nm)
eir 50% end-point ELISA titers obtained against the native hexameric
0.07 (high values)).
Table 2 Mouse PAb reactions against DENV-2 NS1 glycoprotein peptides prepared in the natural and reverse
orientations
Peptide/Epitopea N/Rb Sequencec Average ELISA absorbance (492 nm) of PAbse
C57BL or B10 mouse haplotype anti-DENV-2 NS1glycoprotein PAbsd
C57 S RIII G BR D2N A S(C)
N-TERM + 5-VVSWKNKELKC-15 0.87 0.92 0.78 0.71 0.67 0.70 0.68 0.18
N-TERM - 15-CKLEKNKWSVV-5 0.56 0.58 0.54 0.56 0.43 0.51 0.55 0.14
LD2 + 25-VHTWTEQYK-33 0.67 0.54 1.21 1.32 0.69 0.72 1.02 0.27
LD2 - 33-KYQETWTHV-25 0.44 0.37 0.83 1.24 0.26 0.45 0.77 0.25
24A + 61-TRLENLMWK-69 0.80 0.77 0.79 0.56 0.43 0.45 0.46 0.28
24A - 69-KWMLNELRT-61 0.35 0.32 0.52 0.42 0.41 0.28 0.40 0.25
N'LX1 + 109-TELRYSWKT-117 1.23 1.41 1.01 0.97 1.14 1.16 0.96 0.27
N'LX1 - 117-TKWSYRLET-109 0.98 0.86 0.82 0.88 0.99 1.06 0.89 0.22
LX1 + 113-YSWKTWGKA-121 0.87 1.08 0.44 0.23 0.30 1.16 0.21 0.13
LX1 - 121-AKGWTKWSY-113 0.28 0.39 0.63 0.42 0.34 0.34 0.36 0.18
LX2/1 + 209-TWKIEKASF-217 0.72 0.68 1.04 1.01 0.72 0.50 0.68 0.20
LX2/1 - 217-FSAKEIKWT-209 0.81 1.20 1.15 1.03 1.14 0.65 0.61 0.24
LX2/2 + 267-PWHLGKLEM-275 0.92 0.79 1.02 1.04 0.76 0.68 0.63 0.21
LX2/2 - 275-MELKGLHWP-267 0.98 1.03 1.06 1.12 0.82 0.54 0.67 0.18
24C + 301-TTASGKLIT-309 0.65 0.74 0.61 0.66 0.47 0.40 0.43 0.13
24C - 309-TILKGSATT-301 0.41 0.47 0.51 0.56 0.42 0.39 0.48 0.12
LX2/3 + 331-YGMEIRPLK-339 0.65 0.71 1.24 1.01 0.69 0.81 0.62 0.26
LX2/3 - 339-KLPRIEMGY-331 0.61 1.11 1.21 1.16 0.51 0.66 0.59 0.20
aName of the epitope or MAb 1G5.4-A1-C3 and/or 1C6.3 defined N’LX1, LX2/1, LX2/2 and LX2/3 peptide sequences that contained ELK/KLE-type or KELK/KLEK-type
motifs.
bSynthetic peptide sequences prepared in either the natural (N: +) or reverse (R: -) orientations.
cSequence position and amino acid sequence of the DENV-2 NS1 glycoprotein represented by synthetic peptides prepared both the natural and reverse
orientations. The ELK/KLE-type and KELK/KLEK-type motifs are underlined.
dGroups of C57BL (C57) (H-2b) or congeneic (H-2) B10 mouse strains (B10.S (S), B10.RIII (RIII), B10.BR (BR), B10.D2N (D2N) and B10.A (A)) immunized with the native
hexameric DENV-2 e/sNS1 glycoprotein (gp), or the control protein (ovalbumin) (B10.S(C): (S(C)).
eAverage ELISA absorbance values of mouse PAb pools reacted with duplicate sets of synthetic peptides (standard deviation range: 0.00 (low values) to 0.04 (high
values)). PAb absorbance (Abs) values which were≥ 0.650 against the peptide prepared in the natural orientation that showed≥ 1.50-fold or≥ 2.50-fold RADS
values (Abs against the natural (+)/reverse orientated peptide sequence), are underlined and shown in bold, respectively.
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http://www.biomedcentral.com/1756-0500/5/208reverse orientated synthetic peptide sequences, despite
their strong reactions against the native hexameric
DENV NS1 glycoproteins in ELISA and Western blot
assays (Table 1). The latter findings probably resulted
from the high ELK/KLE-type and KELK/KLEK-type
motif densities on these glycoproteins, which may be fur-
ther increased when they were present in their native
homo-hexameric forms.
RADS values of congeneic mouse strain PAbs against
epitopes on the DENV-2 NS1 glycoprotein
The ability of these RADS value measurements to dissect
the target peptide sequences defined by the congeneic
mouse PAbs, was also investigated. For this evaluation,
RADS values of greater than or equal to 1.50-fold (low
specificities) or 2.50-fold (high specificities) were deter-
mined only when absorbance (Abs) values of greater
than or equal to 0.650 against the natural orientated pep-
tide sequence were obtained.In this study, the PAbs generated by the high-responding
mouse haplotypes (I-Ab: C57BL and I-As: B10.S) had high
3.11-fold (C57BL mice) and 2.77-fold (B10.S mice) RADS
values against the LX1 epitope (Table 2, Table 3). These
results were consistent with their ability to react with the
RLX1 peptide, and cross-react with the NS1 glycoproteins
of all four DENV serotypes (Table 1). Their PAbs also dis-
played lower specificities for: a) the N-TERM epitope
(1.55-fold (C57BL mice) and 1.59-fold (B10.S mice) RADS
values), b) the 24A epitope (2.28-fold (C57BL mice) and
2.40-fold (B10.S mice) RADS values), and c) the N’LX1
peptide by the B10.S mouse PAbs (1.64-fold RADS value),
which all contained KELK/KLEK-type or ELK/KLE-type
motifs (Table 2, Table 3). The 24C epitope was also weakly,
but specifically, identified by these PAbs (1.59 (C57BL
mice) and 1.58 (B10.S mice) RADS values), while the
C57BL mouse PAbs also weakly, but specifically, reacted
with the LD2 epitope (1.52-fold RADS value). As observed
using MAbs 1C6.3 and 1G5.4-A1-C3, these PAbs more
Table 3 Relative antibody discriminating specificity (RADS) values of MAbs and PAbs against the DENV-2 NS1 glycoprotein
peptides
MAb/PAba Relative antibody discriminating specificity (RADS) valuec
Peptide/epitope on DENV-2 NS1 glycoprotein and sequence positionb
N-TM LD2 24A N'LX1 LX1 LX2/1 LX2/2 24 C LX2/3
5-15 25-33 61-69 109-117 113-121 209-217 267-275 301-309 331-339
MAb
1H7.4 * 16.8 * * * * * * *
5H4.3 * * 4.2 * * * * * *
3D1.4 * * * * 15.0 * * * *
1G5.3 * * * * * * * 12.4 *
1C6.3 1.12 1.05 0.47 0.93 * 0.82 1.12 * 1.67
1G5.4-A1-C3 1.10 0.88 0.62 1.26 * * * * 0.97
PAb
C57BL 1.55 1.52 2.28 1.26 3.11 0.89 0.94 1.59 1.07
B10.S 1.59 * 2.40 1.64 2.77 0.57 0.77 1.58 0.64
B10.RIII 1.44 1.46 1.52 1.24 * 0.90 0.96 * 1.02
B10.G 1.27 1.07 * 1.10 * 0.98 0.93 1.18 0.87
B10.BR 1.56 2.65 * 1.15 * 0.63 0.93 * 1.35
B10.D2N 1.37 1.33 * 1.09 * * 1.26 * 1.23
B10.A 1.24 1.33 * * 1.08 1.11 * * *
aMonoclonal antibody (MAb) name or polyclonal antibody (PAb) pools from congeneic mouse strains (C57BL, B10.S, B10.RIII, B10.BR, B10.D2N and B10.A) generated
against the DENV-2 NS1 glycoprotein.
bName of epitope defined by MAb 1H7.4, 5H4.3, 3D1.4 or 1G5.3 or peptide name identified by MAb 1G5.4-A1-C3 and/or 1C6.3 through their reactions with their
ELK/KLE-type or KELK/KLEK-type motifs on the DENV-2 NS1 glycoprotein with their amino acid sequence location (N-TM = peptide N-TERM).
cRelative antibody discriminating specificity (RADS) value, determined from the average ELISA absorbance values of the MAbs or mouse PAb pools against
synthetic peptides prepared in the natural/reverse orientations (fold difference of absorbance against the natural orientated peptide sequence/reverse orientated
peptide sequence). MAb and PAb RADS values were only determined when they had absorbance (Abs) values of≥ 0.650 against the peptide prepared in the
natural orientation. RADS values of≥ 1.50-fold or≥ 2.50-fold are underlined and shown in bold, respectively. Reactions that were Abs< 0.650 against the peptide
sequence prepared in the natural orientation are shown by asterixes.
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http://www.biomedcentral.com/1756-0500/5/208strongly reacted with the LX2/1 peptide sequence when it
was prepared in the reverse orientation but, unlike these
MAbs, they more strongly reacted with the LX2/2 (C57BL
and B10.S mice) and LX2/3 (B10.S mice only) peptide
sequences when these were prepared in the reverse
orientation.
The DENV-2 =DENV-4 ≥DENV-1 =DENV-3 PAb
reaction-profiles generated by the C57BL and B10.S
mice against the NS1 glycoproteins of each DENV sero-
type (Table 1) could therefore be accounted for by their
ability to react: i) with moderately-high RADS values
against the LX1 and 24A epitopes, which were defined
by dengue-complex reactive MAb 3D1.4 and the DENV
-2/-4 reactive MAb 5H4.3, respectively, ii) with lower
RADS values against the LD2 and 24C epitopes, which
were defined by the DENV-2 and DENV-2/-4 NS1
glycoprotein reactive MAbs 1H7.4 and 1G5.3, respect-
ively, and iii) with very low RADS values against mul-
tiple peptide sequences which contained ELK/KLE-type
or KELK/KLEK-type motifs (e.g. N-TERM, LX2/1,
N’LX1 (C57BL mice only), LX2/1, LX2/2 and LX2/3),
that were identified by the DENV-2 complex reactive
MAbs 1G5.4-A1-C3 and/or 1C6.3 (Table 2, Table 3).In contrast, a) the DENV-2 serotype-specific NS1 glyco-
protein reaction profile of the B10.BR mouse PAbs (Table 1)
probably resulted from their moderately-high (2.65-fold)
RADS value against the LD2 epitope (Table 2, Table 3), b)
the weak DENV-2>DENV-1=DENV-3=DENV-4 reac-
tion profile of the B10.RIII mouse PAbs (Table 1) probably
resulted from their low discriminating reaction (1.52-fold
RADS value) against epitope 24A, and non-specific reac-
tions against the multiple peptide sequences defined by
MAb 1G5.4-A1-C3 and/or 1C6.3 (Tables 2, Tables 3), c) the
very weak DENV-1=DENV-2=DENV-4 reaction profile
of the B10.D2N mouse PAbs (Table 1) probably resulted
from its weak and non- specific discriminatory reactions
against the multiple peptide sequences defined by MAb
1G5.4-A1-C3 and/or 1C6.3 (Table 2, Table 3), d) the very
weak DENV-2-type reaction profile of the B10.A
mouse PAbs (Table 1) probably resulted from their
strong reaction against the LD2 epitope (Table 3), but
which was non-specific (Table 2), and e) the inability
of the control B10.S mouse PAbs generated to ovalbu-
min to react with the DENV NS1 glycoproteins
(Table 1), was consistent with their inability to react
with any of these peptide sequences from the DENV-2
Figure 2 MAb 1C6.3 and 1G5.4-A1-C3 reactions against DENV-2 NS1 glycoprotein natural and reverse orientated peptide sequences.
a Peptide name. b Peptide sequence prepared in the natural (+) or reverse (−) orientations. cAmino acid position and single letter amino acid
code for peptide sequence with ELK/KLE-type and KELK/KLEK-type motifs underlined. dAverage ELISA absorbance (490 nm) against each duplicate
synthetic peptide sequence when MAb 1C6.3 and 1G5.4-A1-C3 were diluted to 50 times their 50% end-point ELISA titers obtained against the
native hexameric DENV-2 e/sNS1 glycoprotein (standard deviation range: 0.00 (low values) to 0.04 (high values)).
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reaction profile of the B10.G mouse PAbs (Table 1)
could not, however, be explained by their reactions
against this panel of peptides from the DENV-2 NS1
glycoprotein (Table 2, Table 3).
The RADS methodology therefore accounted for the
mouse PAb reaction profiles obtained with the native
NS1 glycoproteins of each DENV serotype in almost
every case. These results also confirmed that RADS
values of PAbs generated against single LD2, 24A, LX1
and 24C epitopes, defined by MAb 1H7.4, 5H4.3, 3D1.4
and 1G5.3, respectively, as well as against ELK/KLE-type
and KELK/KLEK-type motifs in the N-TERM, N’LX1,
LX2/1, LX2/2 and LX2/3 peptide sequences (defined by
MAb 1G5.4-A1-C3 and/or 1C6.3), were dependent upon
the mouse H2 class II haplotypes.
MAb 1G5.3 reactions with the 24C epitope sequence
containing amino acid substitutions, deletions or cysteine-
bridges
An analysis of the target 24C epitope, defined by MAb
1G5.3, was performed to identify its critical target amino
acid sequence. In this study, the reaction of MAb 1G5.3
with the NS1 glycoproteins of only DENV-2 and DENV-4
was found to be dependent upon the single amino acid
substitution of 303-alanine (A side-chain: -CH3) (299-RTTTASGKLIT-309) by valine (V side-chain: -CH-(CH3)2),
present in the corresponding sequences of the DENV-1
and DENV-3 serotypes (Table 4). This MAb also showed a
strong reaction against the truncated 301-TTASGKLI-307
sequence. The 303-A residue could, however, be success-
fully substituted by a cysteine (C side-chain: -CH2-SH) resi-
due, only when it was oxidized to form an intra-cysteine
bridge with another unnatural C residue (underlined)
present in the same peptide (C-299-RTTTCSGKLIT-
309) (intra-C-C bond). This suggested that rotation of
the oxidized C residue occurred and may, therefore, be
successfully replaced by smaller amino acids (e.g. gly-
cine (G) side-chain: -H; alanine (A) side-chain: -CH3).
MAb 1G5.3 reaction was inhibited when the 305-G
(glycine: -H) was either deleted (299-RTTTASKLIT-
309) or substituted either by: i) the larger hydrophobic
amino acid valine (V side-chain: -CH-(CH3)2) (299-
RTTTASVKLIT-309) or ii) a cysteine residue (under-
lined), even when it was oxidized (C299-RTTTASCK-
LIT-309) to form an intra C-C bond. In addition, MAb
1G5.3 was un-reactive with a peptide designed to create
this epitope by the formation of an intra C-C bond (301-
TTASCGGGCKLIT-309) (data not shown).
These results showed that the reaction of MAb 1G5.3
could accept substitutions in the residues immediately ad-
jacent to the core SGK sequence and that oxidized C
Table 4 MAb 1G5.3 reactions against DENV glycoprotein, HIV-1 gp41 and mammalian blood-clotting factor IX peptides
Agent/Proteina Epitope/peptide name/domain (DOM) (Status)b Peptide sequencec ELISA Absd
DENV-2/NS1 24C 299-RTTTASGKLIT-309 3.547
DENV-4/NS1 24C 299-RTTTASGKLVT-309 4.324
DENV-2/NS1 24C (303-A/V Sub) 299-RTTTVSGKLIT-309 0.236
DENV-2/NS1 24C (Rev) 309-TILKGSATTTR-299 0.232
DENV-2/NS1 24C (Core sequence) 301-TTASGKLI-308 3.264
DENV-2/NS1 24C (298-C Ins/303-A/C Sub/Red) C299-RTTTCSGKLIT-309 1.032
DENV-2/NS1 24C (298-C Ins/303-A/C Sub/Ox Intra) C299-RTTTCSGKLIT-309 3.161
DENV-2/NS1 24C (305-G/V Sub) 299-RTTTASVKLIT-309 0.198
DENV-2/NS1 24C (298-C Ins/305-G/C Sub/Ox Intra) C299-RTTTASCKLIT-309 0.110
DENV-2/NS1 24C (305-G Del) 299-RTTTASKLIT-309 0.125
DENV-1/NS1 N-TERM (Red) 3-GCVINWKGRELKCG-16 0.064
DENV-2/NS1 N-TERM (Red) 3-GCVVSWKNKELKCG-16 0.111
DENV-3/NS1 N-TERM (Red) 3-GCVINWKGKELKCG-16 0.073
DENV-4/NS1 N-TERM (Red) 3-GCVVSWSGKELKCG-16 3.602
DENV-1-4/E Dom III 391-WFKKGSSIG-399 0.111
DENV-1-4/E Dom III (393-KKGSS-397 Inv) 391-WFSSGKKIG-399 0.864
DENV-4/E Dom II (Red) 116-CAKFSCSGKITK-127 1.323
DENV-4/E Dom II (Ox Intra) 116-CAKFSCSGKITK-127 1.951
DENV-4/E Dom II (121-C/G Sub) 116-CAKFSGSGKITK-127 1.221
DENV-4/E Dom III (309-C Ins/Red) 298-SYTMCSGKFSI-308C 0.122
DENV-4/E Dom III (309-C Ins/Ox Intra) 298-SYTMCSGKFSI-308C 0.324
DENV-4/E Dom III (309-C Ins/303-C/G Sub) 298-SYTMGSGKFSI-308C 0.342
Factor IX Gla Dom (7-γE/E, 8-γE/G Subs) 1-YNSGKLEGFV-10 1.791
Factor IX Gla Dom (2-N/A,7-γE/E, 8-γE/G Subs) 1-YASGKLEGFV-10 2.795
HIV-1/gp41 Gnann (Red) 598-LGIWGCSGKLICT-609 2.735
HIV-1/gp41 Gnann (Ox 603-C-608-C Intra) 598-LGIWGCSGKLICT-609 3.673
HIV-1/gp41 Gnann (Red) 598-LGIWGCSGKLICT-609 3.518
HIV-1/gp41 Gnann (Ox 603-C Inter/608-C Inter) 598-LGIWGCSGKLICT-609 3.823
HIV-1/gp41 Gnann (603-C and 608-C/G Subs) 598-LGIWGGSGKLIGT-609 3.642
aInfectious agents as dengue virus type-1 to −4 (DENV-1 to DENV-4) or human immunodeficiency virus-1 (HIV-1) and the protein as the DENV nonstructural-1 (NS1)
or envelope (E) glycoprotein, HIV-1 envelope glycoprotein 41 (gp41) or the mammalian blood-clotting factor IX.
bEpitope name (e.g. the 24C or Gnann epitopes) or peptide (e.g. N-TERM) name from the DENV NS1 glycoprotein or the antigenic domain (Dom II or III) of the
DENV E glycoproteins or the Gla domain (Gla Dom) of blood-clotting factor IX. The peptide status as being prepared in the reverse orientation (Rev), containing a
substitution (Sub) (e.g. 303-A by V substitution = 303-A/V Sub), insertion (Ins) or deletion (Del), or having their cysteine (C) residues reduced (Red) or oxidized (Ox)
to form intra-peptide (Intra) or inter-peptide (Inter) cysteine bonds.
cThe amino acid sequence location, with the peptides prepared in the reverse orientation or containing substituted, inserted or inverted amino acid residues
(underlined).
dAverage ELISA absorbance (490 nm) against duplicate peptides when reacted at a dilution of 50 times their reciprocal 50% end-point ELISA titer obtained against
the native hexameric DENV-2 NS1 glycoprotein (standard deviation range: 0.00 (low values) to 0.09 (high values)). Absorbance values above 1.000 are underlined
and those above 3.000 are shown in bold.
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MAb 1G5.3 reactions with epitopes on the DENV-4 NS1
and E glycoproteins
MAb 1G5.3 cross-reacted with the virion-associated en-
velope (E) glycoproteins (gp60 and its alternative gp55
form) of DENV-2 in immuno-blot assays, and weaklyneutralized all four DENV serotypes [7]. The ability of
this MAb to cross-react with the recently identified
xSGKx-type motifs present on the DENV-4 NS1 and E
glycoproteins was therefore investigated. Such cross-
reactions may then identify a potential ‘antigenic decoy’
role of the DENV-4 NS1 glycoprotein and/or the poten-
tial of MAb 1G5.3 to generate DENV-4 antibody-
enhanced replication (AER).
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the N-TERM epitope present on the NS1 glycoprotein of
DENV-4 (3-GCVVSWSGKELKCG-16), due to its unique
xSGKx sequence amongst the four DENV serotypes, des-
pite being flanked by the large tryptophan (8-W) and
glutamic acid (12-E) residues (underlined) (Table 4).
Interestingly, only the DENV-4 E glycoprotein, amongst
the four DENV serotypes, contained surface-exposed
xSGKx motifs present in the positive orientation within
the corresponding neutralization epitope sequences
within antigenic domain II and III, as determined from
the corresponding sequences in the X-ray crystallo-
graphic analyses of the DENV-2 and DENV-3 E glyco-
proteins [MMDB ID 23080 and 32273] [63,64]. This
suggested that the DENV-4 NS1 glycoprotein could con-
tain two xSGKx epitope motifs, which could prevent
PAb reactions against the surface-exposed xKGSx/
xSGKx-motifs on the DENV-4 E glycoprotein. The reac-
tions of MAb 1G5.3 with these xKGSx/xSGKx motifs
were therefore tested.
MAb 1G5.3 was un-reactive with the DENV-conserved
391-WFKKGSSIG-399 sequence (Table 4), previously
defined by the dengue-complex neutralizing MAb 3A8.1
(393-KKGSSIGQ/KM-410) [8]. MAb 1G5.3, however,
more strongly reacted (Abs 0.864) with a peptide that con-
tained an inverted core 393-KKGSS-397 sequence (391-
WFSSGKKIG-399) which further confirmed its xSGKx
motif orientation-specificity. This MAb strongly reacted
with the surface-exposed 116-CAKFSCSGKITK-127
sequence (Abs 1.323) from domain II of the DENV-4 E
glycoprotein, and its reaction was increased when this
peptide was oxidized to form an intra-C-C bond (Abs
1.951). MAb 1G5.3 showed a slightly weaker reaction
against this sequence when it contained a 121-C (C
side-chain: -CH2-SH) by G (G side-chain: -H) substitu-
tion (116-CAKFSGSGKITK-127), to represent the
rotated C residue. This suggested that substitution of
the 121-C by an alanine residue (A side-chain: -CH3)
was likely to be more suitable, as was present in the 24C
epitope (299-RTTTASGKLI/VT-309) of the DENV-2
and −4 NS1 glycoproteins. MAb 1G5.3 however only
weakly reacted with the 298-SYTMCSGKFSI-308C se-
quence, which was present in domain III of the DENV-4
E glycoprotein, in either the reduced or oxidized forms,
or when the peptide contained a 302-C by G residue
substitution to represent the rotated C residue. These
results were probably due to the location of the large
aromatic phenylalanine (306-F side-chain: -CH2-C6H5)
residue located immediately adjacent to the SGK motif.
These results confirmed the presence of common epi-
topes on the DENV-4 NS1 and E glycoproteins which
was due to the xSGKx ‘antigenic theme’, in addition to
the KELK/KLEK-type and ELK/KLE-type ‘antigenic
themes’ previously identified [6,7].MAb 1G5.3 cross-reaction with a critically-functional site
on mammalian blood-clotting factor IXa
The ability of MAb 1G5.3 to cross-react strongly with the
functional, mammalian-conserved and Ca2+-stabilised/acti-
vated 2-NSGKLEEFV-11 gamma-carboxyglutamic acid-
(γE-) rich (Gla) domain on blood-clotting factor IXa was
investigated. For this study, high-resolution x-ray crystallo-
graphic data were available for this region of the protein
bound by a MAb (10C12) Fab fragment [MMDB ID
25991] [66] or the snake (Trimeresurus flavoviridis) venom
protein, IX/X-bp [MMDB ID 23297 and 23298] [67]. The
MAb 10C12 Fab fragment, which inhibited blood coagula-
tion, displayed hydrophobic interactions with 6-L, 9-F and
10-V (underlined) of this sequence (1-YNSGKLγEγEFV-
10). Each of the amino acids in the 3-SGKL-6 core target
sequence defined by MAb 1G5.3 were highly exposed,
while one COO- group of the 7-γE (side-chain: -CH2-CH-
(COO-)2) residue bound a Ca
2+ ion, the other COO- group
of its side-chain was available for interaction with MAb
1G5.3. The side-chain of its 8-γE residue was instead bur-
ied, due to the interaction of both of its COO- groups with
Ca2+ ions. As such, these amino acids should be suitably
replaced by a normal glutamic acid (7-E side-chain: -CH2-
CH2-COO
-) residue, and a glycine (8-G side-chain: -H)
residue. The tyrosine (1-Y) side-chain was exposed, but the
side-chain of the critical adjacent asparagine (2-N side-
chain: -CH2-C(NH2) = O) residue was rotated to bind a
Ca2+ ion, thereby being unavailable for full interaction with
MAb 1G5.3. Interestingly, this same molecular structure of
the 1-YNSGKLγEγEFV-10 sequence was also identified
when it contained bound Ca2+ or Ca2+ and Mg2+ ions, and
the IX/X-bp snake venom protein [61]. As a result, this 2-
N residue was likely to be more suitably substituted by an
alanine or glycine (A side-chain: -CH3; G side-chain: -H)
residue. These observations were consistent with the strong
binding (Abs 1.791) of MAb 1G5.3 to this peptide
sequence when it contained 7-E and 8-G residues
(1-YNSGKLEGFV-10), and even stronger binding (Abs
2.795) when this peptide also contained a 2-N by A substi-
tution (1-YASGKLEGFV-10) (Table 4). These results may,
therefore, account for the ability of MAb 1G5.3 to generate
dramatic intra-peritoneal haemorrhage in mice [23].
Reaction of MAb 1G5.3 with an immuno-dominant
epitope on human immunodeficiency virus-1 (HIV-1)
glycoprotein 41
HIV-1-infected patients, particularly those with AIDS,
generated PAb responses against the immuno-dominant
599-GIWGCSGKLIC-609 (Gnann epitope) sequence on
the 41 kDa glycoprotein (gp41) of HIV-1, which could be
faithfully represented as an intra- C-C bridged synthetic
peptide [57,58]. The X-ray crystallographic structure of
this peptide (600-IWGCSGKLICTTA-612) had also been
determined [MMDB ID: 73687] [65]. MAb 1G5.3 was
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it was reduced (unnatural), or contained either an inter-
(unnatural) or intra- (natural) cysteine bridge (C-C), or
C by G substitutions (unnatural).
In this study, MAb 1G5.3 reacted with this epitope in
the reduced form (Abs 2.74), but its reaction with it was
dramatically increased when both C (603-C and 608-C)
residues were oxidized to form either the natural intra-C-
C (natural) peptide loop (Abs 3.67), or inter-peptide
(unnatural) C-C bonds (Abs 3.82) (Table 4). The strong re-
action of MAb 1G5.3 with the latter peptide, even before it
was oxidized (pre-oxidation: Abs 3.52; post-oxidation: Abs
3.82), probably resulted from the partial rotation of the
603-C residue due to the presence of the un-cleaved
(I2-sensitive) hydrophobic S-acetamidomethyl (S-Acm: -S-
CH2-NH-CO-CH3) protective group. Similar strong MAb
1G5.3 reactions (Abs 3.64) were observed when this pep-
tide sequence was prepared with 603-C and 609-C by G
substitutions to represent the rotated C side-chains. Thus,
despite MAb 1G5.3 being generated against the DENV-2
NS1 glycoprotein, it showed a similarly strong reaction
against an immuno-dominant epitope on HIV-1 gp41
(Abs 3.55 versus 3.52-3.82) which was previously shown to
generate HIV-1 AER via complement receptor- [59] or,
complement-independent Fcγ-receptor- [60] mediated
mechanisms. MAb 1G5.3 is therefore also likely to gener-
ate AER of this heterologous infectious agent.
Discussion
The main findings from this study were that: a) MAb
and PAb RADS values, and their reactions against large
numbers of peptides that contained amino acid inver-
sions, deletions, substitutions or intra-/inter-C-C bridges,
could be concurrently assessed in the convenient 96-well
ELISA format, b) the measurements of RADS values
allowed discriminating MAb and PAb reactions to be
distinguished from non-discriminating ones using a large
number of peptide sequences to account for their reac-
tion patterns against natural NS1 glycoproteins of all
four DENV serotypes, c) common epitopes were present
on the DENV-2 and −4 NS1 glycoproteins and on a crit-
ical phospholipid-binding site on mammalian blood-
clotting factor IXa which may account for the ability of
MAb 1G5.3 to generate severe haemorrhage in vivo, d)
common motifs on the DENV-4 NS1 and E glycopro-
teins were identified by their xSGKx ‘antigenic theme’
and the reaction of MAb 1G5.3 with the 116–127
peptide sequence in domain II of the DENV-4 E glyco-
protein was increased when it contained an intra-C-C
bridge or amino acid substitutions mimicking more faith-
fully its natural X-ray crystallograph, e) this was the first
report that identified a common determinant on a DENV
protein and another infectious agent (HIV-1 gp41) which
could generate antibody-enhanced replication (AER), andf ) the methodology described may be useful to identify
patients’ PAb reactions that are involved in the pathogen-
esis of DENV, or other infectious and non-infectious
diseases.
Peptide methodology
Importantly, only natural L-amino acid residues were
used to prepare the peptides in both the natural and re-
verse orientations for the RADS value determinations,
rather than using D-amino acid residues as used previ-
ously in the preparation of ‘retro-inverso’ peptides [68].
In this study, all of the peptides except the RLX1 pep-
tide, were covalently attached to uniformly-loaded ali-
phatic spacer molecules on ‘gears/arrowheads’ so that
each amino acid side-chain was exposed for MAb/PAb
binding. This improved technology resulted in much
lower variations in the peptide concentrations and MAb/
PAb reactions [6,7], as was previously observed with the
‘pin’ technology [23,44]. This method was therefore un-
like that in which peptides are adsorbed onto solid-phase
ELISA plates where some of the amino acid side-chains,
particularly of short peptide sequences, would be un-
available for MAb/PAb binding. In the case of the RLX1
peptide, the longer (19-mer) peptide length, and
dimerization via its carboxyl-terminal cysteine (C) resi-
due, as demonstrated for the AFLX1 peptide [6,23],
allowed all of the essential amino acid side-chains of epi-
tope LX1 to be exposed for MAb and PAb reactions
[6,23]. It is possible that this method could have
increased the accessibility to antibodies thereby resulting
in an increased detection of cross-reactions with heterol-
ogous peptide sequences. The cross-reactions of these
MAbs and mouse PAbs from all congeneic (class II)
mouse strains used in this study had previously been
confirmed by their reactions with epitopes and critical
functional sites in multiple proteins of human platelets,
endothelial cells and blood-clotting factor I (fibrinogen)
[6,23] (see below).
Relative antibody discriminating versus non-
discriminating MAb reactions against DENV proteins
Since MAb 3D1.4 showed a highly specific 15.00-fold
RADS value against its DENV complex-conserved LX1
epitope, it was useful for detecting the s/eNS1 glycopro-
teins in DENV-infected patients’ blood/serum samples
using simple, inexpensive and sensitive DIS and N-DIS
dot-blot assays [69], as well as some expensive commer-
cially-available DENV diagnostic assays [70,71].
Antigenic ‘poly-specificity’ of PAbs and MAbs has fre-
quently been reported [9-14]. Thus, despite MAb 1G5.3
having a high RADS value against the target 24C epitope
on the NS1 glycoproteins of DENV-2/-4, it also reacted
strongly with other natural-orientated core target xSGKx
sequence on the DENV-4 E and NS1 glycoproteins, HIV
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clotting factor IXa.
The DENV-2 NS1 and E glycoproteins were shown to
have antigenically co-evolved by immuno-blot analyses
of these glycoproteins from different DENV-2 strains
using MAbs [42]. These results were further supported
by phylogenetic analyses of the genes encoding the E and
NS1 glycoproteins of all DENV serotypes [43]. In this
study, MAb 1G5.3 was used to identify xSGKx motifs
that were uniquely present in the NS1 glycoprotein
N-TERM peptide sequence and 116–127 peptide
sequence of the DENV-4 E glycoprotein (domain II),
which supported these earlier observations. MAb 1G5.3
was previously shown to: i) weakly bind to the flavivirus-
conserved neutralization fusion-sequence on the E glyco-
protein, ii) weakly neutralize all DENV serotypes,
iii) generate intraperitoneal haemorrhage in mice, and iv)
generate a dramatic and lethal AER/AED of a DENV-2
strain [6,45]. Further studies are required to assess the
potential ‘decoy’ effect of the large concentrations of the
NS1 glycoprotein that are secreted con-currently with
virions from DENV-4-infected cells, and whether this
glycoprotein could inhibit or reduce the ability of MAb
1G5.3 to react with this epitope on the DENV-4 E glyco-
protein, and thereby generating its AER resulting in
AED.
Many KELK/KLEK-type and ELK/KLE-type motifs,
defined by MAbs 1C6.3 and 1G5.4-A1-C3, were located in
or immediately flanking the sequential epitopes identified
by four other MAbs (e.g. the 24A and N’LX1 epitopes),
and which were immuno-dominant in both mice and
humans [6,23]. The N’TERM peptide sequence, 1-
DSGCVVSWKNKELKC-15 [6,23], was reported to gener-
ate predominantly an immuno-dominant IgM response in
45% of humans with primary or secondary DENV infec-
tions, which could be detected as early as day 2 after the
onset of febrile illness in some patients [41]. This peptide
sequence also contained a KELK motif (underlined), which
was confirmed to be surface-exposed and antigenic in the
DENV-2 E glycoprotein (156-GKHGKEI/VKIT-165) [6,7].
RADS value analysis would therefore be useful for eluci-
dating whether these human IgM PAbs were generated
against this epitope per se, or whether these IgM PAbs
were generated against similar epitope sequences on the
more immunogenic DENV-2 E glycoprotein. In other
studies, DENV NS1 glycoprotein-reactive IgG PAbs were
only detected during the acute-phase of secondary DENV
infections [41], when most DHF/DSS cases occur [26,28].
The IgG PAbs generated by three (C57BL, B10.S and B10.
BR) of the seven (3/7: 42.9%) congeneic mouse strains
tested, showed only weak specificities (i.e. low RADS
values) against the N-TERM epitope. All of the congeneic
mouse strains instead generated the highest IgG absorb-
ance values against the N’LX1peptide sequence, but wereonly weakly discriminatory (low RADS values). The high-
est RADS values for the PAbs were obtained for PAbs to
the LX1 and 24A epitopes from the C57BL and B10.S
mice, and against the LD2 epitope by the PAbs from the
B10.BR mice, and accounted for their reaction profiles
against the NS1 glycoproteins of each DENV serotype.
These results therefore showed that the immuno-domin-
ance of particular epitopes was dependent on their class II
haplotypes. The X-ray crystallographic structure of the
DENV NS1 glycoprotein has not been determined to date.
The results from this study however strongly suggest that
immunodominant antibody responses were generated
against the ELK/KLE-type/KELK/KLEK-type motifs due to
their high prevalence within sequential epitopes(e.g. the
N-TERM and 24A epitopes) or immediately flanking other
epitopes (e.g. the N'LX1 peptide partially overlapping the
LX1 epitope) that were identified with moderately-high
RADS values by both MAbs and PAbs. The similar reac-
tions of both MAbs 1G5.4-A1-C3 and 1C6.3 with ELK/
KLE-type and KELK/KLEK-type motifs in DENV NS1 and
E glycoprotein sequences when presented in both natural
and reverse orientations suggested that these reactions
were strongly dependent on electrostatic interactions,
while the central residue may contribute to hydrophobic
associations. The importance of ELK/KLE-type motif
density was supported by the finding that these ELK/KLE-
type motifs were more numerous and/or antigenic in sur-
face-exposed regions of the E glycoproteins from virulent
(DSS-associated) DENV-2 and DENV-3 strains, while
MAb 1G5.4-A1-C3 weakly neutralized these DENV strains
[7]. Importantly, the DENV E glycoproteins exist as homo-
dimers, which form homotrimers upon target cell fusion
[63,64] which would increase the reactions of MAbs and
PAbs due to their ELK/KLE-type/KELK/KLEK-type dens-
ities. MAb 1G5.4-A1-C3 is therefore also more likely to
generate the AER of these more virulent DENV strains.
These results also agree with those obtained in several
studies that demonstrated strong direct correlations be-
tween antigenicity and immunogenicity and epitope dens-
ities [46-49].
Reaction of MAb 1G5.3 with mammalian blood-clotting
factor IXa
During the critical stage of disease (DHF/DSS), usually
day 4–5 after the onset of the febrile phase DHF/DSS
(DHF grade I to IV), patients show thrombocytopenia,
haemoconcentration (increased haematocrit percentages)
and may also display spontaneous bleeding (DHF grades
II-IV) [72,73]. Early evidence of bleeding (conjunctival
injection and veni-puncture bleeding), displayed during
the first 72 hours after the onset of fever in the absence
of thrombocytopenia, amongst other clinical criteria, de-
finitively identified DENV-infected patients who subse-
quently developed DHF/DSS [74]. MAb 1G5.3 displayed
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binding site (Gla domain (ω-loop)) of mammalian blood-
clotting factor IXa, which may have accounted for its ability
to generate intra-peritoneal bleeding in mice [23]. This was
supported by X-ray crystallographic analyses of the critical
target sequence on factor IXa bound by MAb 10C12 or the
IX/X-bp snake venom protein, which both inhibited blood-
coagulation [61,66,67]. Interestingly, patients with haemo-
philia type B caused by a single 2- asparagine (2-N) by tyro-
sine (Y) substitution (1-YYSGKLγEγEFV-10) had a 99%
reduction in their factor IXa function [75]. Haemophilia
type B is displayed by severe and often spontaneous haem-
orrhagic disease (Christmas disease), similar to that
observed in some patients with severe DENV disease (DHF
grades II to IV) [72,73]. These findings, therefore,
confirmed the essential role of: i) factor IXa in maintaining
normal haemostasis, despite its very low blood concentra-
tion (44–88 nM: mean 67 nM=0.038 μg/ml) [76], and
ii) the 2-N residue binding to a Ca2+ ion thereby causing its
rotation, and which would result in increased MAb 1G5.3
binding. Reduced functions of factor IXa were however
only found in 17% of patients with DHF/DSS, while 50%
and 100% showed reduced factor VIIa and factor I (fibrino-
gen) functions/concentrations, respectively [77]. Such find-
ings of factor IXa concentrations in DHF/DSS patients
may, therefore, be consistent with the observation that only
mice that possessed the highest responding class II haplo-
types (C57BL: I-Ab and B10.S: I-As) (2/7: 29%) generated
PAbs with relatively low 1.58- and 1.59-fold RADS values
against the 24C epitope in this study.
While an initial study showed that MAb 1G5.4-A1-C3
bound to the corresponding Gla domain peptide sequence
of factor VIIa (1-ANAFLγEγELRP-10) [23], the more re-
cent X-ray crystallographic analysis of this region of factor
VIIa [MMDB ID 70357] [78] showed that both carboxylic
acid groups of 5- and 6-γE residues were bound to Ca2+
ions. MAb 1G5.4-A1-C3 would therefore be unable to
bind the target 6-γELR-9 (ELK-motif ) sequence on acti-
vated factor VIIa. The reduced function of factor VIIa in
DHF/DSS patients may therefore result from either other
biochemical factors, or from their PAb reactions against
other epitopes on this molecule. In contrast, immuno-
dominant PAb responses were generated against these
ELK/KLE-type motifs in all congeneic mouse strains tested
when these animals were either immunized with the
DENV-2 NS1 glycoprotein or infected with live DENV-2,
and all of them reacted with human platelets and fibrino-
gen [6,23]. These ELK/KLE-type motifs were identified by
MAb 1G5.4-A1-C3 in multiple surface-exposed regions of
the human fibrinogen (α- and γ-chains) which were func-
tionally active sites (e.g. xRGDx-motifs and the xRLDGSx-
motif) [23]. PAb responses against ELK/KLE-type motifs
were higher in DSS patients versus DF patients, and DSS
patients sera showed the same high reactions againstmultiple ELK/KLE-type motifs in the DENV-2 NS1 glyco-
protein as MAb 1G5.4-A1-C3 and sera from high respond-
ing congeneic (H-2b and H-2s) mouse strains immunized
with this glycoprotein [6,23]. This is consistent with the
high concentrations of fibrinogen that have been identified
in DSS patients’ circulating immune complexes (CICs)
[45,79] and with the fact that single domain anti-fibrinogen
MAbs generated against the DENV-2 NS1 glycoprotein
prolonged thrombin times in blood-coagulation assays
[80]. It is likely that such PAb reactions may account for
the consistently reduced detection of fibrinogen and
fibrinogen-degradation products in DHF/DSS patients
blood samples [73,79,81]. Further studies are therefore
required to confirm whether DSS patients’ CICs also con-
tain blood-clotting factor VIIa and/or IXa.
Cross-reaction of MAb 1G5.3 with an important epitope
on another infectious agent
In this study, MAb 1G5.3 strongly reacted with the
immuno-dominant epitope on HIV-1 gp41. Initial stud-
ies suggest that PAbs from HIV-1-infected patients also
react with epitopes on the DENV E glycoproteins (data
not shown). This was the first identification of common
determinants on DENV and another infectious agent,
and such poly-reactive antibodies may generate AER of
these heterologous viruses. Importantly, the ability of
PAbs generated against HIV-1 gp41 or MAb 1G5.3 to
generate DENV-4 AER/AED can be further tested under
physiological conditions in vivo, using a recently devel-
oped DENV AER/AED model [24].
Potential design of improved peptide sequences
The oxidation of cysteine residues to form natural loops
was essential for optimal antigenicity of a protective epi-
tope on the hepatitis B virus [82] and a diagnostic pep-
tide on HIV-1 gp41 [57,58]. The addition and oxidation
of cysteine residues flanking a loop-configured epitope
defined by an anti-DENV E glycoprotein MAb which
neutralized all DENV serotypes [8] is also likely to in-
crease its antigenicity. Increased antigenicity was
observed in this study by the substitution of the C by A
or G residues (C side-chain: -CH3; G side-chain: -H) cor-
responding to the rotation of the oxidized C residues in
the DENV-4 E glycoprotein. Previously, a C by G amino
acid substitution in the conserved flavivirus E glycopro-
tein fusion sequence (101-WGNGCGLFG-109) was also
tested [8]. In this previous study, this single 105-C by G
(G side-chain: -H) substitution dramatically increased
the binding of flavivirus group (MAb 4G2 and 2C5.1)
and sub-group (MAb 2F2.1) reactive neutralizing MAbs,
which could also be gauged by their increased RADS
values from 1.64, 1.67 and 1.31 to 2.60, 2.57 and 2.33, re-
spectively against these peptide sequences [8]. These
results were consistent with the rotation of the 105-C
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107-L residues required for MAb 4G2 binding [83], and
the weak ability (65% inhibition at 1 mM) of a synthetic
peptide that contained a 105-C by S (serine) (side chain:
-CH2-OH) to block a neutralizing MAb binding to its
target fusion sequence on DENV particles [84]. In
addition, new improved hybrid target sequences, defined
by protective anti-DENV prM and E MAbs have also
been designed [62]. The substitution of the critical 2-N
by G or A, and 7γE by E and 8γE by G are also likely to
more closely mimic the activated phospho-lipid binding
site of activated (Ca2+-stabilized) human blood-clotting
factor IX (IXa), as shown in the structure of this critical
site determined by X-ray crystallography [66,67].Potential applications for DHF/DSS pathogenesis studies
We described simple, definitive prognostic clinical criteria
that could specifically identify DENV-infected patients,
during the early acute phase of disease (≤ 72 hours after
the onset of fever), who will subsequently develop DHF/
DSS versus DF or had another febrile illness [74]. Early
acute phase PAb samples from DENV-infected patients
against a synthetic peptide identified those patients who
subsequently developed DSS, but not DHF or DF [45]. A
panel of MAbs has been tested for their ability to generate
DENV AER/AED in vivo at high concentrations using our
mouse model [24], to prevent confusion with the ability of
neutralizing MAbs to generate DENV AER when diluted
beyond their effective neutralizing concentrations [26]. It
is therefore essential for a tetravalent DENV vaccine to
generate adequate and sustainable levels of neutralizing
antibodies against each of the four DENV serotypes [37].
Of further concern is that such a vaccine may also place
infants (mean age: 6-months), who have low and broadly
DENV cross-reactive IgG1 antibodies during their weaning
stage, at high risk for developing DHF/DSS in primary
DENV infections as was shown in Cuba, Singapore [85]
and Viet Nam [86,87].
RADS values, obtained against the peptide sequences
on the DENV E glycoproteins and auto-antigens, defined
by those MAbs that generated DENV AER/AED in our
lethal in vivo DSS model [24] will be determined and
assessed in the future for their potential prognostic
values for DHF/DSS patients to support the definitive
clinical criteria already identified [74].Conclusions
In conclusion, the RADS value methodology, together with
amino acid deletion, substitution and inter- and intra-C-C
bridge formation analyses, that were evaluated using mul-
tiple synthetic peptides covalently attached by their carb-
oxyl-termini in the standard 96-well ELISA format, wasvery useful to gauge the discriminating reactions against
epitopes that were recognized by PAbs or MAbs using syn-
thetic peptides. The methodology described was therefore
useful to: a) confirm the occurrence of cross-reactions be-
tween epitopes by their RADS values in: i) the same viral
protein (e.g. DENV-4 NS1 glycoprotein), ii) another DENV
glycoprotein (e.g. the DENV-4 E glycoprotein), iii) another
infectious agent (e.g. HIV-1), and iv) a mammalian glyco-
protein (e.g. blood-clotting factor IXa), and could be used
to design more antigenic peptide sequences. In the latter
case, amino acid substitutions in synthetic peptide
sequences can be used to represent rotated amino acids in
the DENV-4 (116-CAKFSCSGKITK-127) E glycoprotein,
and the activated form of the human blood-clotting factor
IX (1-YNSGKLγEγEFV-10), in order to mimic their native
conformations. These findings are important for under-
standing the pathogenesis of DHF/DSS caused by either
auto-immune reactions [6,23] or DENVAER, which can be
confirmed in vivo by their abilities to generate severe, lethal
multi-organ disease syndrome (MODS) [24], and may lead
to the design of suitable prognostic peptides for DHF/DSS
patients. Importantly, the methodology described will also
be useful for assessing discriminating MAb or PAb reaction
specificities against epitopes on proteins of any pathogen,
allergen or auto-antigen.
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